Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

NSPR
InspireMD, Inc.
stock NASDAQ

At Close
May 1, 2026 3:58:30 PM EDT
1.15USD-2.542%(-0.03)9,174,535
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-1.18)0
After-hours
May 1, 2026 4:59:56 PM EDT
1.46USD+26.957%(+0.31)381,209
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
08:00AM EST  InspireMD to Present at the 16th Biennial Scientific Meeting of   GlobeNewswire Inc
Jan 18, 2022
08:12AM EST  InspireMD Announces Live Case Broadcast at ISET 2022 Conference   GlobeNewswire Inc
Nov 9, 2021
11:44AM EST  InspireMD, Inc. Common Stock Q3 EPS $(0.53) Beats $(0.82) Estimate, Sales $1.07M Miss $1.20M Estimate   Benzinga
11:44AM EST  CORRECTION: InspireMD, Inc. Common Stock Q3 EPS $(0.53) Beats $(0.82) Estimate, Sales $1.07M Miss $1.20M Estimate   Benzinga
11:36AM EST  InspireMD, Inc. Common Stock Q3 EPS $(0.96) Misses $(0.82) Estimate, Sales $1.07M Miss $1.20M Estimate   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
07:30AM EST  InspireMD Reports Third Quarter 2021 Financial Results and   GlobeNewswire Inc
Nov 3, 2021
06:22PM EDT  InspireMD Announces Publication Of 12-Month Results Of CGuard EPS SIBERIA Trial In Journals Of The American College of Cardiology: Cardiovascular Interventions   Benzinga
Oct 26, 2021
08:30AM EDT  InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens.   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  Mid-Morning Market Update: Markets Mixed; JPMorgan Posts Upbeat Earnings   Benzinga
01:38PM EDT  InspireMD Reports Received Reimbursement Approval For CGuard Embolic Prevention System From French National Authority For Health   Benzinga
08:30AM EDT  InspireMD Receives Reimbursement Approval for   GlobeNewswire Inc
Sep 15, 2021
01:11PM EDT  InspireMD Granted Canadian Patent Titled 'INTRAVASCULAR ANEURYSM TREATMENT DEVICE AND METHODS'   Benzinga
Aug 10, 2021
05:34PM EDT  InspireMD Reports Narrower Loss In Q2 As Revenue Rebounds On Procedural Recovery   Benzinga
07:25AM EDT  InspireMD Q2 EPS $(0.46) Beats $(0.63) Estimate, Sales $1.04M Miss $1.10M Estimate   Benzinga
07:00AM EDT  InspireMD Announces Strong Second Quarter 2021 Financial Results   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 4, 2021
08:30AM EDT  InspireMD to Report Second Quarter 2021 Financial Results on   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
08:31AM EDT  InspireMD Enrolls And Treats First Patients At Ballad Health System In U.S. Registration C-Guardian Clinical Trial Of CGuard EPS   Benzinga
08:30AM EDT  InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Companys U.S. registration C-Guardian trial of CGuard EPS.   GlobeNewswire Inc
Jul 6, 2021
10:06AM EDT  InspireMD Granted U.S. Patent Titled 'Intravascular aneurysm treatment device and methods'   Benzinga
Jun 2, 2021
08:04AM EDT  InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.   GlobeNewswire Inc
May 27, 2021
08:00AM EDT  InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq   GlobeNewswire Inc
May 25, 2021
01:25PM EDT  Insperity ClinicalTrials.gov Study Record Detail For Co.'s 'Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting (C-Guardians),' Listing Shows Study Not Yet Recruiting   Benzinga
May 21, 2021
08:31AM EDT  InspireMD Commences Trading On Nasdaq-CM   Benzinga
08:30AM EDT  InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Companys shares will commence trading on The Nasdaq Capital Market (Nasdaq-CM), today, May 21, 2021, under the symbol NSPR.   GlobeNewswire Inc
May 14, 2021
11:30AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Says 'This Is A Long Play,' Says Looking For Investors Who Understand The Story   Benzinga
11:30AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Says Once Customers Convert To C-Guard They Usually Stay   Benzinga
11:28AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Says 'This Is Very Much A Touch Business'   Benzinga
11:27AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Says 'We Hope' China Revenue Is Similar Pathway To U.S.; Sees Finish In 2 To 2.5 Years   Benzinga
11:16AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Says 'Taking On Stroke As Our Main Tarket'   Benzinga
11:15AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Highlights Co's Management   Benzinga
11:15AM EDT  From BZ Global Small-Cap Event: InspireMD CEO Marvin Slosman Says Co's Goal Is To Change The Way Carotid Artery Disease Is Treated   Benzinga
06:48AM EDT  Schedule For Benzinga's Global Small Cap Conference Friday, May 14, 2021   Benzinga
06:00AM EDT  InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.   GlobeNewswire Inc
May 13, 2021
09:48AM EDT  InspireMD Files For U.S. Patent Titled 'Stent assembly and methods for treatment via body lumens'   Benzinga
May 12, 2021
06:09AM EDT  InspireMD Appoints Kathryn Arnold To Its Board   RTTNews
06:00AM EDT  InspireMD Announces Appointment of Katie Arnold to Board of Directors   GlobeNewswire Inc
May 11, 2021
12:47PM EDT  Earnings Scheduled For May 11, 2021   Benzinga
12:20PM EDT  InspireMD shares were trading lower after the company reported Q1 EPS and sales results down from last year.   Benzinga
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
06:26AM EDT  InspireMD Q1 EPS $(0.53) Down From $(0.43) YoY, Sales $1.01M Down From $1.03M YoY   Benzinga
06:00AM EDT  Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021   GlobeNewswire Inc
04:14AM EDT  Earnings Scheduled For May 11, 2021   Benzinga
May 10, 2021
04:53PM EDT  InspireMD Reports Will Transfer Its Listing To Nasdaq, Effective May 21, 2021   Benzinga
04:05PM EDT  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys shares have been approved for listing on The Nasdaq Capital Market (Nasdaq). Trading is expected to begin onMay 21, 2021, under the symbol NSPR on the Nasdaq.   GlobeNewswire Inc
May 6, 2021
06:00AM EDT  InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.   GlobeNewswire Inc
Apr 29, 2021
06:00AM EDT  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.   GlobeNewswire Inc
Apr 19, 2021
06:08AM EDT  InspireMD Announces Co. Has Submitted Its Application To Join The Nasdaq Capital Market   Benzinga
06:00AM EDT  InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate developments.   GlobeNewswire Inc
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 14, 2021
04:05PM EDT  InspireMD Announces 1-for-15 Reverse Stock Split Effective As Of April 26, 2021   Benzinga
04:05PM EDT  InspireMD Announces 1-for-15 Reverse Stock Split   GlobeNewswire Inc
Mar 22, 2021
07:54AM EDT  InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders   Benzinga
07:53AM EDT  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Companys Special Meeting of Stockholders.   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data   Benzinga
09:15AM EST  InspireMD Q4 EPS $(0.10) Misses $(0.08) Estimate, Sales $158.00K Miss $1.00M Estimate   Benzinga
06:30AM EST  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth quarter and year ended December 31, 2020.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For March 9, 2021   Benzinga
Mar 8, 2021
10:11AM EST  Preview: InspireMD's Earnings   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 2, 2021
08:27AM EST  InspireMD Granted US Patent Titled 'Stent assembly and methods for treatment via body lumens'   Benzinga
06:00AM EST  InspireMD, Inc. (NYSE American: NSPR) (InspireMD or the Company), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal fourth quarter and year-end 2020 financial results on Tuesday, March 9, 2021 before the market opens.   GlobeNewswire Inc
Feb 24, 2021
06:09AM EST  InspireMD Says Has Engaged Hart Clinical Consultants To Conduct A Clinical Trial Of CGuard Carotid Stent System In The US   Benzinga
06:00AM EST  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
Feb 9, 2021
06:00AM EST  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.   GlobeNewswire Inc
Feb 8, 2021
04:05PM EST  InspireMD Announces Closing of an Upsized $20.7 Million   GlobeNewswire Inc
Feb 4, 2021
08:37AM EST  InspireMD Announces Pricing Of Upsized $18M Underwritten Public Offering; Offering Comprised Of 29,032,258 Units At $0.62/Share   Benzinga
08:30AM EST  InspireMD Announces Pricing of Upsized $18 Million Underwritten   GlobeNewswire Inc
Feb 3, 2021
08:37AM EST  InspireMD Partner For Intended Registration And Distribution Of CGuard EPS In Mainland China   Benzinga
08:32AM EST  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.   GlobeNewswire Inc
Jan 26, 2021
06:30AM EST  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live demonstration, during the Leipzig Interventional Congress being held virtually from January 25-29, 2021.   GlobeNewswire Inc
Jan 11, 2021
09:14AM EST  InspireMD Says On Jan 11, Co & A.G.P./Alliance Global Partners Increased To $10.4M Of Shares Of Common Stock That May Be Sold Under Sales Agreement   Benzinga
Nov 9, 2020
06:32AM EST  InspireMD, Inc. Common Stock Q3 EPS $(0.06) Beats $(0.18) Estimate, Sales $980.00K Beat $400.00K Estimate   Benzinga
06:30AM EST  Third quarter 2020 revenue returns to pre-COVID-19 levels   GlobeNewswire Inc
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 3, 2020
07:53AM EST  InspireMD, Inc. (NYSE American: NSPR) (Company), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.   GlobeNewswire Inc
Nov 2, 2020
06:30AM EST  InspireMD, Inc. (NYSE American: NSPR) (InspireMD or the Company), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal third quarter 2020 financial results on Monday, November 9, 2020 before the market opens.   GlobeNewswire Inc
Oct 16, 2020
11:53AM EDT  Alliance Global Partners Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $0.7   Benzinga
Oct 13, 2020
06:30AM EDT  InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to InspireMDs Board of Directors.   GlobeNewswire Inc
Oct 6, 2020
06:30AM EDT  InspireMD, Inc. Appoints Patrick Jamnik as Vice President of   GlobeNewswire Inc
Oct 2, 2020
01:47PM EDT  Hearing InspireMD Was Granted Allowance for a Patent Application Titled 'Stent Assembly and Methods for Treatment via Body Lumens'   Benzinga
Sep 8, 2020
06:47AM EDT  InspireMD: FDA Grants Approval To Proceed With A Pivotal Study Of CGuard Carotid Stent System, CARENET-III   RTTNews
06:36AM EDT  InspireMD Announces Approval Of Investigational Device Exemption For Pivotal Study Of CGuard Carotid Stent System   Benzinga
06:30AM EDT  InspireMD Announces Approval of Investigational Device Exemption   GlobeNewswire Inc
Sep 3, 2020
06:30AM EDT  InspireMD Announces the European Society of Cardiology 2020   GlobeNewswire Inc
Aug 25, 2020
06:30AM EDT  InspireMD to Present at the LD Micro 500 Virtual Conference on   GlobeNewswire Inc
Aug 10, 2020
06:35AM EDT  InspireMD Regains Compliance with NYSE AMERICAN Listing Standards   Benzinga
06:30AM EDT  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained compliance with the NYSE Americans continued listing standards.   GlobeNewswire Inc
Aug 5, 2020
10:41AM EDT  InspireMD shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.   Benzinga
06:52AM EDT  InspireMD Q2 EPS $(0.20) Beats $(0.35) Estimate, Sales $313.00K Beat $200.00K Estimate   Benzinga
06:41AM EDT  In the second quarter the Company was granted approval to market itsCGuard MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard MicroNET stent   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Jul 29, 2020
04:05PM EDT  UPDATE: InspireMD to Report Second Quarter 2020 Financial Results   GlobeNewswire Inc
Jul 28, 2020
08:30AM EDT  InspireMD to Report Second Quarter 2020 Financial Results on   GlobeNewswire Inc
Jul 23, 2020
08:15AM EDT  InspireMD Gains Registration Clearance Of Its CGuard Embolic Prevention System (EPS) In Brazil   Benzinga
08:00AM EDT  InspireMD Gains Registration Clearance of its   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC